
|Articles|December 24, 2012
Supplements and Featured Publications
- Improving Clinical and Managed Care Outcomes in Rheumatoid arthritis: a Focus on Comparative Effecti
- Volume 18
- Issue 13 Suppl
Improving Clinical and Managed Care Outcomes in Rheumatoid Arthritis: A Focus on Comparative Effectiveness of Current Treatments
Advertisement
Instructions
After reading “Improving Clinical and Managed Care Outcomes in Rheumatoid Arthritis: A Focus on Comparative Effectiveness of Current Treatments,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
almost 14 years ago
Comparative Effectiveness of Current Treatments for Rheumatoid Arthritisalmost 14 years ago
Implications for Managed Care and Specialty Pharmacy in Rheumatoid ArthritisAdvertisement
Related to this article

The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply

At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
3
FDA Expands Mavacamten Label to Include Children With oHCM
4
Proposed Medicare Rate Cuts Draw AASM Opposition Ahead of Final Rule
5


